Protea Biosciences Group, Inc. 4
4 · Protea Biosciences Group, Inc. · Filed Apr 4, 2017
Insider Transaction Report
Form 4
HARRIS LEONARD P
Director
Transactions
- Other
Class B Warrant (right to buy)
2017-03-24+3,440,000→ 7,926,556 totalExercise: $0.11From: 2017-03-24Exp: 2022-03-24→ Common Stock (3,440,000 underlying) - Other
Common Stock
2017-03-24+344,000→ 6,675,068 total - Other
Class A Warrant (right to buy)
2017-03-24+3,440,000→ 7,926,556 totalExercise: $0.09From: 2017-03-24Exp: 2018-09-24→ Common Stock (3,440,000 underlying)
Footnotes (3)
- [F1]Leonard P. Harris held $258,000 of outstanding principal indebtedness and accrued unpaid interest of the Issuer ("Unsecured Debt"). On March 24, 2017, Mr. Harris exchanged $258,000 of Unsecured Debt of the Issuer, for units of the Issuer's equity securities, consisting of (a) an aggregate of 3,440,000 shares of common stock, $0.0001 par value per share, of the Issuer ("Common Stock") valued at $0.075 per share, (b) 18 month Class A warrants to purchase 3,440,000 shares of Common Stock at an exercise price of $0.09 per share, and (c) five year Class B warrants to purchase another 3,440,000 shares at an exercise price of $0.1125 per share.
- [F2]The shares of Common Stock reported in Column 5 and 7 are the number of shares of Common Stock issuable upon exercise of the Class A Warrant and/or Class B Warrant (collectively, "Warrants").
- [F3]Includes 7,509,889 shares of Common Stock to be acquired upon the exercise of warrants and 416,667 shares of Common Stock to be acquired upon the exercise of stock options.